explore -WSS

explore

author：explore 2025-08-23 08:54:33 - browse：43497

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Ibogaine psychedelic therapy for opioid addiction unlikely, official says

focus

WSS

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Healthy food access boosts outcomes in two studies

Chinese researcher claims birth of first gene

Type 2 diabetes prevention programs work at large scale: study

What Kate Middleton's cancer revelation might teach the world

Yancopoulos of Regeneron works to expand Dupixent success

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Psychedelics group wrestles with new pharma identity

Experimental asthma app from Apple and Anthem shows promise

Walensky prepares to leave CDC — and Congress — behind

FDA reorg will put new emphasis on investigations, sources say

Supreme Court strikes down use of affirmative action

Texas board proposes rules on abortion law emergency exemption

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Ohio still needs to do more to protect the right to abortion

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: Illumina, CRISPR, Regeneron

focus

Pfizer, Moderna say biotech, pharma drug development is a sprint

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Healthy food access boosts outcomes in two studies

Yancopoulos of Regeneron works to expand Dupixent success

U.K. officials, researchers try to ease path for bespoke genetic treatments

Chinese researcher claims birth of first gene

focus

leisure time

focus

knowledge